(UroToday.com) The field of advanced prostate cancer has rapidly progressed over the past 15 years. Prior to the publication of TAX-327, there were no proven life-prolonging therapies for patients with metastatic castration-resistant prostate cancer (mCRPC). Since that time, there have been many new agents that have proven survival benefits including taxane-based chemotherapy, agents targeting the androgen axis, and bone-targeting agents. However, many patients will exhaust efficacious treatment options. Cabazitaxel is typically used in the second-line chemotherapy setting. In a plenary abstract presentation in the Poster Highlights Session: Prostate Cancer session at the 2021 ASCO Genitourinary Cancers Symposium (ASCO GU), Dr. Pobel and colleagues assess the feasibility and efficacy of cabazitaxel multiple rechallenges in patients with mCRPC.